Overall, these studies indicate that a high pre-treatment or post-treatment serum CRP/ALB ratio is a valuable independent biomarker for prediction of poor outcomes in HCC patients after treatment with various therapies. This evidence concerns the gene ALB and hepatocellular carcinoma.